In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer

Show full item record



Permalink

http://hdl.handle.net/10138/317007

Citation

Randen-Brady , R , Carpen , T , Jouhi , L , Syrjänen , S , Haglund , C , Tarkkanen , J , Remes , S , Mäkitie , A , Mattila , P S , Silen , S & Hagström , J 2019 , ' In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer ' , Human Pathology , vol. 90 , pp. 97-105 . https://doi.org/10.1016/j.humpath.2019.05.006

Title: In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer
Author: Randen-Brady, Reija; Carpen, Timo; Jouhi, Lauri; Syrjänen, Stina; Haglund, Caj; Tarkkanen, Jussi; Remes, Satu; Mäkitie, Antti; Mattila, Petri S.; Silen, Suvi; Hagström, Jaana
Contributor: University of Helsinki, HUSLAB
University of Helsinki, Korva-, nenä- ja kurkkutautien klinikka
University of Helsinki, HUS Head and Neck Center
University of Helsinki, HUS Abdominal Center
University of Helsinki, Helsinki University Hospital Area
University of Helsinki, Department of Pathology
University of Helsinki, HUS Head and Neck Center
University of Helsinki, HUS Head and Neck Center
University of Helsinki, HUS Head and Neck Center
Date: 2019-08
Language: eng
Number of pages: 9
Belongs to series: Human Pathology
ISSN: 0046-8177
URI: http://hdl.handle.net/10138/317007
Abstract: Current human papillomavirus (HPV) detection methods in oropharyngeal squamous cell carcinoma (OPSCC) have varying sensitivity and specificity. We aimed to compare different HPV-detection methods against the test used in clinical practice, ie, p16 immunohistochemistry (IHC) and to evaluate whether another HPV-detection test additional to p16 IHC would be worthwhile in OPSCC specimens. The study cohort comprised 357 consecutive OPSCC patients during two time periods: 2000-2009 and 2012-2016. From tumor tissue slides, HPV mRNA via in situ hybridization (ISH), HPV DNA via ISH and HPV DNA via polymerase chain reaction (PCR) were detected. The results of these methods were compared with p16 IHC results. Additionally, clinicopathological factors were compared with the methods studied. The sensitivity of HPV mRNA ISH, HPV DNA ISH and HPV DNA PCR were 93.4%, 86.3%, and 83.5%, respectively. The corresponding specificity was 92.4%, 95.3%, and 89.1%, respectively. The negative predictive value for p16 IHC was highest (89.0%) when using mRNA ISH, and followed by DNA ISH (83.5%). ISH for high-risk HPV E6/E7 mRNA was found to be a highly specific and sensitive method for detecting HPV in OPSCC. As p16 protein may be overexpressed due to HPV-independent mechanisms, all p16 IHC positive OPSCCs should be considered for retesting using mRNA ISH in order to verify transcriptionally active HPV. This is especially critical when considering de-escalated treatment approaches for patients with HPV-positive tumors and still maintaining favorable outcomes for this subgroup of patients. (C) 2019 Elsevier Inc. All rights reserved.
Subject: Oropharynx
Carcinoma
Viral infection
RNA
DNA
Polymerase chain reaction
SQUAMOUS-CELL CARCINOMA
TREATMENT DE-ESCALATION
HUMAN-PAPILLOMAVIRUS DETECTION
NECK-CANCER
P16 IMMUNOHISTOCHEMISTRY
CRITICAL-ISSUES
HEAD
VALIDATION
DIAGNOSIS
PCR
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
In_situ_hybridi ... n_oropharyngeal_cancer.pdf 780.0Kb PDF View/Open
1_s2.0_S0046817719300917_main.pdf 2.051Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record